个人简历

1988年中山医科大学临床医学专业毕业后一直中山大学肿瘤防治中心工作，2003年被派往香港中文大学威尔斯亲王医院和香港大学玛丽医院交流学习，2004年在美国匹兹堡大学器官移植中心作访问学者。近30年来一直致力于肝癌的临床综合治疗，尤其擅长于肝癌的手术切除、局部消融、血管性介入等多学科治疗。早期肝癌利用现代医疗新技术对肿瘤进行术前和术中的精确评估定位，手术过程应用先进的手术设备进行精细化的解剖，既精准切除肿瘤又保留正常肝组织，使患者获得最佳疗效，减少创伤并快速康复。对多结节型肝癌和合并有门静脉癌栓的中晚期肝癌治疗前进行全面评估，为每一位制订一套合理化多学科联合的个体化综合治疗方案，以期获得更好疗效。基于在这领域的突出研究成果，作为总执笔或参与编写多个肝癌诊疗指南及专家共识，这些专家共识和指南已被广泛应用于指导临床一线医师。包括：肝细胞肝癌合并门静脉癌栓多学科综合治疗中国专家共识（2016年版）；肝细胞肝癌合并门静脉癌栓多学科团队综合治疗广东专家共识(2015版)；肝癌多学科综合治疗团队建立--广东专家共识。临床研究重点集中在早期肝癌的精细化手术治疗，肝癌合并门静脉癌栓和中晚期肝癌的合理化、序贯综合治疗以及肝癌术后复发高危人群的有效辅助性治疗。基础研究主要集中在肝癌术后复发转移的相关机制研究和肝癌合并脉管侵犯的发生机制探讨。主持国家自然基金项目并参与多项国家级攻关课题研究，在国内外知名期刊发表论文100多篇，其中SCI论文50多篇。参与获得教育部科技奖、广东省科技进步奖和中华医学科技奖等成果奖5项，主编由人民卫生出版社出版《小肝癌多学科治疗》,多次应邀在报纸和电视台等新媒体进行科普宣传。

研究领域

肝胆系统肿瘤的诊断与治疗，尤擅长肝癌的手术切除、局部消融、血管性介入等多学科综合治疗。在早期肝癌的精细化手术治疗、肝癌合并门静脉癌栓和中晚期肝癌的多学科综合治疗积累了丰富的临床经验。

近期论文

1.Wang JH, Zhong XP, Zhang YF, Wu XL, Li SH, Jian PE, Ling YH, Shi M, Chen MS, Wei W, Guo RP. Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell death & disease. 2017 Sep 07;8(9):e3043. 2.Xiao CZ, Wei W, Guo ZX, Zhang MY, Zhang YF, Wang JH, Shi M, Wang HY, Guo RP. MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. Journal of cancer research and clinical oncology. 2017 Feb;143(2):263-73. 3.Zhong C, Zhang YF, Huang JH, Wang ZY, Chen QY, Su LT, Liu ZT, Xiong CM, Tao Z, Guo RP. The Chinese medicine, Jianpi Huayu Decoction, inhibits the epithelial mesenchymal transition via the regulation of the Smad3/Smad7 cascade. American journal of translational research. 2017;9(6):2694-711. PubMed PMID: 28670362. 4.Li SH, Wang QX, Yang ZY, Jiang W, Li C, Sun P, Wei W, Shi M, Guo RP. Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. World journal of gastroenterology. 2017 May 7;23(17):3122-32. 5.Lu LH, Zhang YF, Wei W, Shi M, Guo RP. Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2017 Aug 24. 6.Zhang YF, Zhou J, Wei W, Zou RH, Chen MS, Lau WY, Shi M, Guo RP. Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. British journal of cancer. 2016 Oct 25;115(9):1039-47. 7.Zhang YF, Wei W, Wang JH, Xu L, Jian PE, Xiao CZ, Zhong XP, Shi M, Guo RP. Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. OncoTargets and therapy. 2016;9:4239-46. 8.Zhang YF, Le Y, Wei W, Zou RH, Wang JH, OuYang HY, Xiao CZ, Zhong XP, Shi M, Guo RP. Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis. Oncotarget. 2016 Jun 21;7(25):38845-56. 9.Zhang YF, Guo RP, Zou RH, Shen JX, Wei W, Li SH, OuYang HY, Zhu HB, Xu L, Lao XM, Shi M. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. European radiology. 2016 Jul;26(7):2078-88. 10.Zhang YF, Guo RP, OuYang HY, Shen JX, Zhao J, Tan GS, Le Y, Wei W, Shi M. Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. Liver international : official journal of the International Association for the Study of the Liver. 2016 Oct;36(10):1516-24. 11.Wang, J.H., Wei, W., Xu, J., Guo, Z.X., Xiao, C.Z., Zhang, Y.F., Jian, P.E., Wu, X.L., Shi, M., Guo, R.P., Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma. Oncotarget 2015, 6(33), 35116-28. 12.Li Shaohua Wang Qiaoxuan Sun Peng Li Qing Yang Zhongyuan Shi Ming Wei Wei Guo Rongping. Surgical Strategy for Hepatocellular Carcinoma Patients with Portal/Hepatic Vein Tumor Thrombosis. PLOS ONE June 15, 2015 13.Zhong, C., Li, M.Y., Chen, Z.Y., Cheng, H.K., Hu, M.L., Ruan, Y.L., Guo, R.P., MicroRNA-200a inhibits epithelial-mesenchymal transition in human hepatocellular carcinoma cell line. International journal of clinical and experimental pathology 2015, 8(9), 9922-31. 14.Zhang, Y.F., Wei, W., Guo, Z.X., Wang, J.H., Shi, M., Guo, R.P., Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Japanese journal of clinical oncology 2015, 45(9), 837-43. 15.Zhang, Y.F., Guo, R.P., Zou, R.H., Shen, J.X., Wei, W., Li, S.H., OuYang, H.Y., Zhu, H.B., Xu, L., Lao, X.M., Shi, M., Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. European radiology 2015. 16.Xiao, C.Z., Wei, W., Guo, Z.X., Li, S.H., Zhang, Y.F., Wang, J.H., Shi, M., Guo, R.P., A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection. Oncology letters 2015, 10(5), 2787-2794.. 17.Wang, J.H., Wei, W., Guo, Z.X., Shi, M., Guo, R.P., Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. Journal of translational medicine 2015, 13, 41. 18.Zhong, C., Li, H.D., Liu, D.Y., Xu, F.B., Wu, J., Lin, X.M., Guo, R.P., Clinical study of hepatectomy combined with Jianpi Huayu Therapy for hepatocellular carcinoma. Asian Pacific journal of cancer prevention : APJCP 2014, 15(14), 5951-7.